A Phase 1 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab in Subjects With B-Cell Non-Hodgkin's Lymphoma

Trial Profile

A Phase 1 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab in Subjects With B-Cell Non-Hodgkin's Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Inotuzumab ozogamicin; Rituximab
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Nov 2016 Last checked against ClinicalTrials.gov record.
    • 20 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top